Clyde Biosciences

Executive Summary

Clyde Biosciences is a UK-based private company specializing in preclinical cardiotoxicity and safety testing through its proprietary CellOPTIQ platform, which utilizes human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). The platform is designed to assess drug-induced arrhythmia risk and cardiac efficacy, aligning with the FDA-endorsed Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative. As an official CiPA member, Clyde Biosciences supports the pharmaceutical industry in reducing late-stage drug attrition due to cardiac liabilities. The company's technology also holds potential in neuroscience, given the role of ion channels in both cardiac and neuronal function. Despite limited public financial disclosures and no announced funding rounds, the company's involvement in regulatory standardization positions it as a key player in the safety pharmacology space. Its platform could expand into CNS drug screening, leveraging its expertise in electrophysiology and ion channel profiling.

Upcoming Catalysts (preview)

• Q3 2026CiPA regulatory guidance update or qualification by FDA/ICH70% success
• Q4 2026Partnership or licensing deal with major pharmaceutical company40% success
• Q2 2027Expansion of CellOPTIQ platform into CNS ion channel screening50% success